Immunovant: A Portfolio Pruning

The transaction, detailed in a filing with the Securities and Exchange Commission – a document as thrilling as watching paint dry, yet occasionally revealing – leaves Immunovant occupying 11.4% of Alpine’s 13F AUM. A reduction, certainly, but hardly an abandonment. Consider, if you will, a collector deciding to part with a particularly iridescent, yet occasionally troublesome, butterfly from their collection. It remains a prized specimen, merely…less densely populated within the display case.








